Proinflammatory cytokines and DHEA-S in women with fibromyalgia: Impact of psychological distress and menopausal status

Journal of Pain Research

Volumn 7, Issue , 2014, Pages 707-716

  Sturgeon, John A ^a   Darnall, Beth D ^a   Zwickey, Heather L ^b   Wood, Lisa J ^c   Hanes, Douglas A ^b   Zava, David T ^d   Mackey, Sean C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b National College of Natural Medicine   (United States)

^c MGH INSTITUTE OF HEALTH PROFESSIONS   (United States)

^d ZRT Laboratories   (United States)

Author keywords

Cytokines; Fibromyalgia; Inflammation; Psychological distress

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; PRASTERONE SULFATE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGING; ANDROGEN BLOOD LEVEL; ANXIETY DISORDER; ARTICLE; BECK DEPRESSION INVENTORY; CATASTROPHIZING; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEPRESSION; DISEASE ASSOCIATION; FEMALE; FIBROMYALGIA; HUMAN; INFLAMMATION; LOW BACK PAIN; MENOPAUSE; MENTAL STRESS; MIDDLE AGED; PAIN ASSESSMENT; PAIN SEVERITY; PREMENOPAUSE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SELF REPORT; SYMPTOMATOLOGY; UPREGULATION;

EID: 84916934387     PISSN: 11787090     EISSN: 11787090     Source Type: Journal    
DOI: 10.2147/JPR.S71344     Document Type: Article

References (66)

1. Wolfe F, Brähler E, Hinz A, Häuser W. Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care Res (Hoboken). 2013;65(5):777-785.
2. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010;62(5):600-610.
3. Wolfe F, Clauw DJ, Fitzcharles M-A, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol. 2011;38(6):1113-1122.
4. Wolfe F, Walitt BT, Häuser W. What is fibromyalgia, how is it diagnosed and what does it really mean? Arthritis Care Res (Hoboken). 2014;66(7):969-971.
5. Clauw DJ. Fibromyalgia: more than just a musculoskeletal disease. Am Fam Physician. 1995;52(3):843-851, 853-844.
6. Nicassio PM, Moxham EG, Schuman CE, Gevirtz RN. The contribution of pain, reported sleep quality, and depressive symptoms to fatigue in fibromyalgia. Pain. 2002;100(3):271-279.
7. Finan PH, Zautra AJ, Davis MC, Lemery-Chalfant K, Covault J, Tennen H. Genetic influences on the dynamics of pain and affect in fibromyalgia. Health Psychol. 2010;29(2):134.
8. Buskila D, Sarzi-Puttini P, Ablin JN. The genetics of fibromyalgia syndrome. Pharmacogenomics. 2007;8(1):67-74.
9. Wallace D, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman M. Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology (Oxford). 2001;40(7): 743-749.
10. Giacomelli C, Talarico R, Bombardieri S, Bazzichi L. The interaction between autoimmune diseases and fibromyalgia: risk, disease course and management. Expert Rev Clin Immunol. 2013;9(11): 1069-1076.
11. Watkins LR, Maier SF, Goehler LE. Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states. Pain. 1995;63(3):289-302.
12. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446-457.
13. Di Franco M, Iannuccelli C, Valesini G. Neuroendocrine immunology of fibromyalgia. Ann N Y Acad Sci. 2010;1193(1):84-90.
14. Gür A, Karakoç M, Nas K, Denli A, Saraç J. Cytokines and depression in cases with fibromyalgia. J Rheumatol. 2002;29(2):358-361.
15. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65(9):732-741.
16. Üçeyler N, Häuser W, Sommer C. Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. BMC Musculoskelet Disord. 2011;12(1):245.
17. Wang H, Moser M, Schiltenwolf M, Buchner M. Circulating cytokine levels compared to pain in patients with fibromyalgia: a prospective longitudinal study over 6 months. The J Rheumatol. 2008;35(7):1366-1370.
18. Bazzichi L, Rossi A, Massimetti G, et al. Cytokine patterns in fibromyalgia and their correlation with clinical manifestations. Clin Exp Rheumatol. 2007;25(2):225.
19. Straub R, Schuld A, Mullington J, Haack M, Scholmerich J, Pollmacher T. The endotoxin-induced increase of cytokines is followed by an increase of cortisol relative to dehydroepiandrosterone (DHEA) in healthy male subjects. J Endocrinol. 2002;175(2):467-474.
20. Spencer NF, Norton SD, Harrison LL, Li G-Z, Daynes RA. Dysregulation of IL-10 production with aging: possible linkage to the age-associated decline in DHEA and its sulfated derivative. Exp Gerontol. 1996;31(3):393-408.
21. Mikkelsson M. One year outcome of preadolescents with fibromyalgia. J Rheumatol. 1999;26(3):674-682.
22. Epstein SA, Kay G, Clauw D, et al. Psychiatric disorders in patients with fibromyalgia: a multicenter investigation. Psychosomatics. 1999;40(1):57-63.
23. Simon N, McNamara K, Chow C, et al. A detailed examination of cytokine abnormalities in major depressive disorder. Eur Neuropsychopharmacol. 2008;18(3):230-233.
24. Maninger N, Wolkowitz OM, Reus VI, Epel ES, Mellon SH. Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). Front Neuroendocrinol. 2009;30(1):65-91.
25. Takebayashi M, Kagaya A, Uchitomi Y, et al. Plasma dehydroepiandrosterone sulfate in unipolar major depression. J Neural Transm. 1998;105(4-5):537-542.
26. Dhabhar FS, Burke HM, Epel ES, et al. Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression. J Psychiatr Res. 2009;43(11):962-969.
27. O’Donovan A, Hughes BM, Slavich GM, et al. Clinical anxiety, cortisol and interleukin-6: evidence for specificity in emotion-biologyrelationships. Brain Behav Immun. 2010;24(7):1074-1077.
28. Dell’Osso L, Carmassi C, Massimetti E, et al. P01-143-gender differences in the correlations between cortisol levels or DHEA-S/cortisol ratio and panic-agoraphobic dimensions in healthy subjects. Eur Psychiatry. 2011;26:143.
29. Loerbroks A, Thomas GN, Engeland CG, Hollands MA, Fischer JE, Bosch JA. Age-dependent and-independent associations between depression, anxiety, DHEAS, and cortisol: from the MIPH Industrial Cohort Studies (MICS). Psychoneuroendocrinology. 2012;37(7):929-936.
30. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38(1):19-28.
31. Licastro F, Candore G, Lio D, et al. Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immun Ageing. 2005;2(8):1-14.
32. Kiecolt-Glaser JK, Preacher KJ, MacCallum RC, Atkinson C, Malarkey WB, Glaser R. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc Natl Acad Sci U S A. 2003;100(15):9090-9095.
33. Bruunsgaard H, Andersen-Ranberg K, Jeune B, Pedersen AN, Skinhøj P, Pedersen BK. A high plasma concentration of TNF-α is associated with dementia in centenarians. J Gerontol A Biol Sci Med Sci. 1999;54(7): M357-M364.
34. Burns EA, Goodwin JS. Immunodeficiency of aging. Drugs Aging. 1997;11(5):374-397.
35. Rozenberg S, Bosson D, Peretz A, Caufriez A, Robyn C. Serum levels of gonadotrophins and steroid hormones in the post-menopause and later life. Maturitas. 1988;10(3):215-224.
36. Rohleder N, Schommer NC, Hellhammer DH, Engel R, Kirschbaum C. Sex differences in glucocorticoid sensitivity of proinflammatory cytokine production after psychosocial stress. Psychosom Med. 2001; 63(6):966-972.
37. Pietschmann P, Gollob E, Brosch S, et al. The effect of age and gender on cytokine production by human peripheral blood mononuclear cells and markers of bone metabolism. Exp Gerontol. 2003;38(10):1119-1127.
38. Pamuk ÖN, Dönmez S, Çakir N. Increased frequencies of hysterectomy and early menopause in fibromyalgia patients: a comparative study. Clin Rheumatol. 2009;28(5):561-564.
39. Ross RL, Jones KD, Bennett RM, Ward RL, Druker BJ, Wood LJ. Preliminary evidence of increased pain and elevated cytokines in fibromyalgia patients with defective growth hormone response to exercise. Open Immunol J. 2010;3:9.
40. Davis SR, Burger HG. Clinical review 82: androgens and the postmenopausal woman. J Clin Endocrinol Metab. 1996;81(8):2759-2763.
41. Overlie I, Moen M, Morkrid L, Skjæraasen J, Holte A. The endocrine transition around menopause: a five years prospective study with profiles of gonadotropines, estrogens, androgens and SHBG among healthy women. Acta Obstet Gynecol Scand. 1999;78(7):642-647.
42. Beck A, Steer R, Brown G. Manual for the BDI-II. San Antonio, TX: Psychological Corporation; 1996.
43. Beekman AT, Deeg D, Van Limbeek J, Braam A, De Vries M, Van Tilburg W. Criterion validity of the Center for Epidemiologic Studies Depression scale (CES-D): results from a community-based sample of older subjects in The Netherlands. Psychol Med. 1997;27(1):231-236.
44. Turk DC, Okifuji A. Detecting depression in chronic pain patients: adequacy of self-reports. Behav Res Ther. 1994;32(1):9-16.
45. Magni G, Moreschi C, Rigatti-Luchini S, Merskey H. Prospective study on the relationship between depressive symptoms and chronic musculoskeletal pain. Pain. 1994;56(3):289-297.
46. McCracken LM, Zayfert C, Gross RT. The Pain Anxiety Symptoms Scale: development and validation of a scale to measure fear of pain. Pain. 1992;50(1):67-73.
47. McCracken LM, Gross RT. Does anxiety affect coping with chronic pain? Clin J Pain. 1993;9(4):253-259.
48. Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale: development and validation. Psychol Assess. 1995;7(4):524-532.
49. Osman A, Barrios FX, Kopper BA, Hauptmann W, Jones J, O’Neill E. Factor structure, reliability, and validity of the Pain Catastrophizing Scale. J Behav Med. 1997;20(6):589-605.
50. Osman A, Barrios FX, Gutierrez PM, Kopper BA, Merrifield T, Grittmann L. The Pain Catastrophizing Scale: further psychometric evaluation with adult samples. J Behav Med. 2000;23(4):351-365.
51. Van Damme S, Crombez G, Bijttebier P, Goubert L, Van Houdenhove B. A confirmatory factor analysis of the Pain Catastrophizing Scale: invariant factor structure across clinical and non-clinical populations. Pain. 2002;96(3):319-324.
52. Price DD, McGrath PA, Rafii A, Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain. 1983;17(1):45-56.
53. Du JY, Sanchez P, Kim L, Azen CG, Zava DT, Stanczyk FZ. Percutaneous progesterone delivery via cream or gel application in postmenopausal women: a randomized cross-over study of progesterone levels in serum, whole blood, saliva, and capillary blood. Menopause. 2013;20(11):1169-1175.
54. Osman A, Barrios FX, Osman JR, Schneekloth R, Troutman JA. The Pain Anxiety Symptoms Scale: psychometric properties in a community sample. J Behav Med. 1994;17(5):511-522.
55. Roelofs J, McCracken L, Peters ML, Crombez G, van Breukelen G, Vlaeyen JW. Psychometric evaluation of the Pain Anxiety Symptoms Scale (PASS) in chronic pain patients. J Behav Med. 2004;27(2):167-183.
56. Frerichs RR, Aneshensel CS, Clark VA. Prevalence of depression in Los Angeles county. Am J Epidemiol. 1981;113(6):691-699.
57. Giesecke T, Williams DA, Harris RE, et al. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum. 2003;48(10):2916-2922.
58. Crombez G, Eccleston C, Van den Broeck A, Goubert L, Van Houdenhove B. Hypervigilance to pain in fibromyalgia: the mediating role of pain intensity and catastrophic thinking about pain. Clin J Pain. 2004;20(2):98-102.
59. Ang DC, Moore MN, Hilligoss J, Tabbey R. MCP-1 and IL-8 as pain biomarkers in fibromyalgia: a pilot study. Pain Med. 2011;12(8): 1154-1161.
60. Ceko M, Bushnell MC, Fitzcharles M-A, Schweinhardt P. Fibromyalgia interacts with age to change the brain. Neuroimage Clin. 2013;3:249-260.
61. Patacchioli FR, Monnazzi P, Simeoni S, et al. Salivary cortisol, dehydroepiandrosteronesulphate (DHEA-S) and testosterone in women with chronic migraine. J Headache Pain. 2006;7(2):90-94.
62. Finset A, Øverlie I, Holte A. Musculo-skeletal pain, psychological distress, and hormones during the menopausal transition. Psychoneuroendocrinology. 2004;29(1):49-64.
63. Gerwin RD. A review of myofascial pain and fibromyalgia: factors that promote their persistence. Acupunct Med. 2005;23(3):121-134.
64. Craft RM. Modulation of pain by estrogens. Pain. 2007;132:S3-S12.
65. Raison V. Neurobiology of depression, fibromyalgia and neuropathic pain. Front Biosci. 2009;14:5291-5338.
66. Geiss A, Rohleder N, Anton F. Evidence for an association between an enhanced reactivity of interleukin-6 levels and reduced glucocorticoid sensitivity in patients with fibromyalgia. Psychoneuroendocrinology. 2012;37(5):671-684.